Pure Global AI
NCT06304545Not yet recruiting

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Long-course Concurrent Chemoradiotherapy Combined With Camrelizumab in the Neoadjuvant Treatment of Locally Advanced/Low Anus-preserving Rectal Cancer: a Phase II Single-arm Study.
Harbin Medical UniversityPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Rectal Cancer
Drug/Device/Intervention
Camrelizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Harbin Medical University
Timeline & enrollment
Phase
Phase 2
Start date
Mar 15, 2024
End date
Mar 15, 2027
Enrollment
48 participants
Primary outcome

Pathological Complete Response rate

Summary

This is a single-arm, phase II clinical study aim to evaluate the efficacy and safety of
 long-term concurrent chemoradiotherapy combined with camrelizumab as a neoadjuvant therapy in
 the treatment of locally advanced/low rectal cancer requiring anus preservation.

ICD-10 classifications
Malignant neoplasm of rectumCarcinoma in situ: RectumBenign neoplasm: RectumSecondary malignant neoplasm of large intestine and rectumCarcinoma in situ: Rectosigmoid junction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06304545
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06304545 through Pure Global AI's free database. This Phase 2 trial is sponsored by Harbin Medical University and is currently Not yet recruiting. The study focuses on Rectal Cancer. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.